Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Trevi Therapeutics
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kilogram per meter square (kg/m\^2) at Screening.
Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the principal investigator (PI) or designee.
You may not be if
Positive results for coronavirus infection (COVID-19).
History or presence of alcohol or drug abuse.
Positive urine drug or alcohol results.
Smoker who has used nicotine containing products within the last 3 months.
History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.
Hemoglobin, absolute neutrophil count, or platelet levels outside of the reference range at Screening.
History of prolonged QT syndrome or a QTc interval.
Abnormal liver function at Screening or historical or concurrent liver disease.
Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
History of difficulty donating blood or donation of blood or plasma within 56 days of Screening.
Participation in another clinical study within 30 days of the baseline visit.
Clareo Health | A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
